These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 23620671)

  • 1. Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.
    Rahmathulla G; Hovey EJ; Hashemi-Sadraei N; Ahluwalia MS
    Onco Targets Ther; 2013; 6():371-89. PubMed ID: 23620671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
    Chen R; Cohen AL; Colman H
    Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab for the treatment of recurrent glioblastoma.
    Chamberlain MC
    Clin Med Insights Oncol; 2011; 5():117-29. PubMed ID: 21603247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
    Chamberlain MC
    Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.
    Shirai K; Siedow MR; Chakravarti A
    J Oncol; 2012; 2012():193436. PubMed ID: 21804824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in high-grade gliomas: past, present, and future.
    Curry RC; Dahiya S; Alva Venur V; Raizer JJ; Ahluwalia MS
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):387-97. PubMed ID: 25797685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of recurrent high-grade gliomas.
    Wen PY; Brandes AA
    Curr Opin Neurol; 2009 Dec; 22(6):657-64. PubMed ID: 19770658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal antibodies in high-grade gliomas].
    Chekhonin IV; Leopold AV; Gurina OI; Semenova AV
    Vestn Ross Akad Med Nauk; 2014; (9-10):131-9. PubMed ID: 25816654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
    Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
    Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
    Scott BJ; Quant EC; McNamara MB; Ryg PA; Batchelor TT; Wen PY
    Neuro Oncol; 2010 Jun; 12(6):603-7. PubMed ID: 20156808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.
    Hanson JA; Hsu FP; Jacob AT; Bota DA; Alexandru D
    Perm J; 2013; 17(4):68-74. PubMed ID: 24361023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
    Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
    Gururangan S; Fangusaro J; Poussaint TY; McLendon RE; Onar-Thomas A; Wu S; Packer RJ; Banerjee A; Gilbertson RJ; Fahey F; Vajapeyam S; Jakacki R; Gajjar A; Goldman S; Pollack IF; Friedman HS; Boyett JM; Fouladi M; Kun LE
    Neuro Oncol; 2014 Jan; 16(2):310-7. PubMed ID: 24311632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma.
    Abrams DA; Hanson JA; Brown JM; Hsu FP; Delashaw JB; Bota DA
    J Clin Neurosci; 2015 Jan; 22(1):35-9. PubMed ID: 25481268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.